A Study of Oral Ibogaine in Opioid Withdrawal

Important Inclusion Criteria for both Stages 1 and 2: * Males and females between 18 years and 55 years of age. * For Stage 1, healthy volunteers; recreational opioid use is allowed but not required for inclusion in the study. * For Stage 2, opioid-dependent subjects (DSM-IV) seeking medically supervised opioid withdrawal and presenting with an OOWS score ≥ 5 on Day 1, prior to dosing. * Self-report of at least 1 prior positive hallucinogen drug experience that included a meaningful altered state of consciousness. Hallucinogenic substances can include psilocybin, LSD, MDMA or other classic hallucinogens. * Females that are not of child-bearing potential as defined within the protocol. * Males who agree to use 1 of the acceptable contraceptive regiments and not to donate sperm from the first study drug administration to at least 90 days after the last drug administration or who are unable to procreate (as defined within the protocol). * For Stage 1, negative urine tests for drugs of abuse (opiates, benzodiazepines, amphetamines, cannabinoids, cocaine, barbiturates, and phencyclidine), and CNS (central nervous system) prescription drugs (SSRIs \[selective serotonin reuptake inhibitors\], SNRIs \[serotonin-norepinephrine reuptake inhibitors\], mood stabilizers) both at screening and within approximately 7 days prior to dosing, and negative alcohol test. * For Stage 2, negative blood and urine tests for methadone, buprenorphine, mitragynine, non-opioid drugs of abuse (benzodiaze…